CureVac starts mRNA vaccine trial, Interprotein uses AI in drug discovery and South Korea's Chong Kun and Hanmi make clinical progress.

2019 has already brought one industry-shaking event in Japan with the formal completion of the Takeda-Shire deal. But how will this play out and what else can we expect in this key market over the next year?

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.

The pharma division of the diversified Japanese chemicals and materials group Asahi Kasei has signed a collaborative research agreement with RaQualia Pharma aimed at the discovery of new therapeutics against a specific (but unidentified) ion channel target.